BRAF and hypertensive disorder: There is no specific evidence to suggest one class of antihypertensive agent over another in the management of BRAF inhibitor/MEK inhibitor–associated hypertension, but we suggest that ACE inhibitors or angiotensin receptor blockers should be used in patients with coexisting LVSD or proteinuria and in the absence of contraindications.